The innovative provider of antimalarial medicines

Most of the countries where malaria is endemic are countries with economic problems. Many pharmaceutical companies are not interested in investing huge resources in the R&D and commercialization of antimalarials, because the return on investment is not very promising.

Nevertheless, based on Mepha’s Mission and Vision, this company is committed to providing those markets with Top Swiss Quality and efficacious antimalarials at fair prices.

Mepha is one of the innovative providers of leading antimalarial medicines. This infectious disease poses a steadily increasing problem in the tropical regions of the world. Mepha works on malaria control in collaboration with the World Health Organization (WHO), tropical institutes, local authorities and international aid organizations. Mepha offers medicines for both prophylaxis and treatment of malaria. Mepha has also consistently followed its strategy of optimizing galenical forms and was the first to provide a thermostable rectal form, Rectocaps™, for antimalarial drugs (patent protected). Further, a first fixed dose ACT, specifically for small children has been developped, Artequin™ Paediatric.

Mepha carries out its own clinical research. The latest result of this research is a combination therapy of artesunate and mefloquine, called Artequin™. As Mepha is always concerned about patient compliance, a special blister was designed for Artequin™. Regardless of their educational level no patient will have any difficulty in taking the medicine in the appropriate way.